FibroGen Inc
Biopharmaceutical company engaged in development and commercialization of therapeutics to treat anemia and fibrotic diseases.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding FibroGen's stock with a target price of $5.75, indicating potential growth.
Financial Health
FibroGen is showing strong revenue and profit margins, with positive cash flow indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FGEN
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and approvals can materially affect valuation, though outcomes are uncertain and performance may vary.
Small‑Cap Volatility
A market cap near $45M means the stock can swing widely on news; risk management and diversification are important.
Regulatory Impact
Approvals or restrictions in key markets shape commercial prospects, and regulatory shifts can change the investment thesis.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
